Scott Kopetz
M.D. Anderson Cancer Center · MD Anderson · Academic and Community Cancer Research United
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Scott Kopetz as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:15 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT07318389 · ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerM.D. Anderson Cancer Center · recruiting · Dynamic Tumor Resistance, Metastatic Colorectal Cancer · principal investigator
- N/ANCT05292859 · Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRsAlaunos Therapeutics · completed · Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer · principal investigator
- Ph1/Ph2NCT05194735 · Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid TumorsAlaunos Therapeutics · terminated · Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer · principal investigator
- N/ANCT05124743 · HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid TumorsAlaunos Therapeutics · terminated · Ovarian Cancer, Endometrial Cancer, Colo-rectal Cancer · principal investigator
- Ph1NCT04046445 · Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal CancerAmal Therapeutics · active not recruiting · Colorectal Cancer, MSS, Stage IV Colon Cancer · principal investigator
- Ph2NCT03981614 · Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal CancerAcademic and Community Cancer Research United · completed · Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8 · principal investigator
- Ph2NCT03549338 · Sym004 Versus Futuximab or Modotuximab in Patients With mCRCSymphogen A/S · terminated · Metastatic Colorectal Cancer, Colorectal Cancer Metastatic, Carcinoma · principal investigator
- N/ANCT01196130 · Colorectal Cancer Umbrella Protocol - Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC Program) Screening ProtocolM.D. Anderson Cancer Center · completed · Colorectal Cancer · principal investigator
- Ph1NCT00501410 · FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal CancerM.D. Anderson Cancer Center · completed · Colorectal Cancer · principal investigator
- Ph2NCT00354978 · Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer PatientsM.D. Anderson Cancer Center · completed · Colorectal Cancer · principal investigator
- Ph3NCT00305643 · Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal CancerM.D. Anderson Cancer Center · terminated · Breast Cancer, Colorectal Cancer, Pain · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Genomics and Gene Regulation ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2026 · $170,449 awarded in 2026Same name and institution; not confirmed by an ID
- Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2022 to 2026 · $476,200 awarded in 2026Same name and institution; not confirmed by an ID
- Colorectal Cancer Molecular Subtype Assay Development and ValidationUH3CA207101 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2021 to 2023 · $149,772 awarded in 2023Same name and institution; not confirmed by an ID
- MD Anderson Cancer Center SPORE in Gastrointestinal CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2023 · $2,203,749 awarded in 2023Same name and institution; not confirmed by an ID
- Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsiesR01CA218230 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2018 to 2022 · $650,719 awarded in 2022Same name and institution; not confirmed by an ID
- MDACC-PREDICTU24CA220325 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2020 to 2022 · $657,521 awarded in 2022Same name and institution; not confirmed by an ID
- Project 2: Building Combinatorial Therapies against KRAS-mutant Colorectal and Pancreatic CancerU54CA224065 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2020 to 2022 · $96,541 awarded in 2022Same name and institution; not confirmed by an ID
- Colorectal Cancer Molecular Subtype Assay Development and ValidationUH2CA207101 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2018 to 2019 · $163,706 awarded in 2019Same name and institution; not confirmed by an ID
- Tumor Heterogeneity and Acquired Resistance to EGFR InhibitionR01CA184843 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2015 to 2019 · $612,599 awarded in 2019Same name and institution; not confirmed by an ID
- Therapeutic Strategies for Patients With BRAF Mutant Colorectal CancerR01CA187238 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2014 to 2018 · $332,000 awarded in 2018Same name and institution; not confirmed by an ID
- Stress Signaling Pathways and Resistance in Colorectal CancerR01CA172670 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2013 to 2017 · $332,000 awarded in 2017Grant number is on one of their registry trials
- Src inhibition in Colorectal CancerK23CA136980 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2008 to 2012 · $134,796 awarded in 2012Same name and institution; not confirmed by an ID
- MicroRNAs and other non-coding RNAs in Colorectal MetastasisR01CA135444 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2009 to 2010 · $315,833 awarded in 2010Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2011 to 2026Named on NCT03981614
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:15 UTC. The ranking covers the 200 most relevant of 61 PubMed records, and a shared surname and initials can bring in a namesake. All 61 on PubMed
- 2,327 citationsRCR 75.2
- 1,198 citationsRCR 43.0
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.J Clin Oncol · 2015568 citationsRCR 14.9
- 454 citationsRCR 23.9
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.J Clin Oncol · 2015434 citationsRCR 11.6
- 409 citationsRCR 9.0
- Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).J Clin Oncol · 2021295 citationsRCR 15.5
- Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.Lancet Oncol · 2022286 citationsRCR 17.0
- Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.Cancer Discov · 2016198 citationsRCR 5.4
- 190 citationsRCR 6.4